Home Newsfeeds Redburn Partners Initiates Coverage On PepsiCo with Sell Rating

Redburn Partners Initiates Coverage On PepsiCo with Sell Rating

Redburn Partners analyst Charlie Higgs initiates coverage on PepsiCo (NASDAQ:PEP) with a Sell rating.

byBenzinga Newsdesk

November 4, 2022

1 minute read

Redburn Partners analyst Charlie Higgs initiates coverage on PepsiCo (NASDAQ:PEP) with a Sell rating.

INmune Bio Data At ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence Of Cancer Killing Memory Like NK Cells In Patients With AML/MDS Following Treatment With INKmune

By Benzinga Newsdesk

December 8, 9:10 AM

INmune Bio, Inc. (NASDAQ:INMB) ("INMB" or "the Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system

INMB

Aegis Capital Reiterates Buy on GigaCloud Tech, Maintains $26 Price Target

By Benzinga Newsdesk

March 20, 11:50 AM

Aegis Capital analyst Rommel Dionisio reiterates GigaCloud Tech (NASDAQ:GCT) with a Buy and maintains $26 price target.

GCT

Analysts See Softened Timelines For CRISPR Therapeutics’ Sickle Cell Candidate In US

By Vandana Singh

August 9, 3:26 PM

Barclays says that CRISPR Therapeutics AG’s (NASDAQ: CRSP) Q2 FY22 earnings release was largely incremental, highlighting the progress of multiple clinical programs, including the…

BLUE